We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

10 hedge funds and large institutions have $1.14M invested in Eterna Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.03% → 0.02% (-0.02%)

5% less capital invested

Capital invested by funds: $1.19M → $1.14M (-$56.9K)

9% less funds holding

Funds holding: 11 → 10 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
Sippican Capital Advisors
Massachusetts
+$54.2K
2
UBS Group
UBS Group
Switzerland
+$15K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$40.6K
2
Renaissance Technologies
Renaissance Technologies
New York
-$18.1K
3
Morgan Stanley
Morgan Stanley
New York
-$6.02K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.5K
5
CS
Credit Suisse
Switzerland
-$386
Name Holding Trade Value Shares
Change 		Change in
Stake
CPWM
1
Cypress Point Wealth Management
Texas
$321K – – –
NW
2
Naviter Wealth
Arkansas
$271K – – –
Corient Private Wealth
3
Corient Private Wealth
Florida
$214K – – –
BlackRock
4
BlackRock
New York
$79.4K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$64.8K -$40.6K -27 -35%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$48.9K – – –
SCA
7
Sippican Capital Advisors
Massachusetts
$45.9K +$54.2K +36 New
Renaissance Technologies
8
Renaissance Technologies
New York
$44K -$18.1K -12 -26%
BWP
9
Baldwin Wealth Partners
Massachusetts
$32.2K – – –
UBS Group
10
UBS Group
Switzerland
$13.1K +$15K +10 New
CHA
11
Carmichael Hill & Associates
Maryland
$255 – – –
MA
12
Montag & Associates
Georgia
$238 – – –
Morgan Stanley
13
Morgan Stanley
New York
$170 -$6.02K -4 Closed
Group One Trading
14
Group One Trading
Illinois
$67 – – –
Wells Fargo
15
Wells Fargo
California
$54 – – –
Citigroup
16
Citigroup
New York
$53 – – –
APC
17
Aspire Private Capital
North Carolina
$34 – – –
Bank of America
18
Bank of America
North Carolina
$31 – – –
Fidelity Investments
19
Fidelity Investments
Massachusetts
$4 – – –
TRCT
20
Tower Research Capital (TRC)
New York
– -$1.5K -1 Closed
CS
21
Credit Suisse
Switzerland
– -$386 – –

ERNA Hedge Fund Activity: Q1 2023 in Review

10 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2023, worth a combined $1.14M — down 4.8% from $1.19M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ERNA and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest buyer was Sippican Capital Advisors, opening a new position worth an estimated $54.2K. The largest seller was Vanguard Group, cutting an estimated $40.6K.

  • 10 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2023, down from 11 in Q4 2022.
  • Funds reported $1.14M of Eterna Therapeutics stock for Q1 2023, down 4.8% quarter-over-quarter.
  • 2 funds opened new Eterna Therapeutics positions in Q1 2023 and 3 closed out, a net change of -1 holder.
  • The largest Eterna Therapeutics buyer in Q1 2023 was Sippican Capital Advisors, an estimated $54.2K added.
  • The largest Eterna Therapeutics seller in Q1 2023 was Vanguard Group, an estimated $40.6K sold.

Based on aggregated 13F filings for Q1 2023.